1. Long non-coding RNA (lncRNA): A potential therapeutic target in acute lung injury
- Author
-
Syed Mansoor Ali, Almaz Zaki, Tasneem Fatma, M. Shadab Ali, Anita Chopra, and Vijay Hadda
- Subjects
ARDS ,Lung ,business.industry ,RNA ,Inflammation ,Cell Biology ,respiratory system ,Pulmonary compliance ,Lung injury ,medicine.disease ,Bioinformatics ,Biochemistry ,Long non-coding RNA ,Pathophysiology ,respiratory tract diseases ,medicine.anatomical_structure ,medicine ,medicine.symptom ,business ,Molecular Biology ,Genetics (clinical) - Abstract
Acute Lung Injury (ALI) and its severe form Acute Respiratory Distress Syndrome (ARDS) are the major cause of ICU death worldwide. ALI/ARDS is characterized by severe hypoxemia and inflammation that leads to poor lung compliance. Despite many advances in understanding and management, ALI/ARDS is still causing significant morbidity and mortality. Long non-coding RNA (lncRNA) is a fast-growing topic in lung inflammation and injury. lncRNA is a class of non-coding RNA having a length of more than 200 nucleotides. It has been a center of research for understanding the pathophysiology of various diseases in the past few years. Multiple studies have shown that lncRNAs are abundant in acute lung injury/injuries in mouse models and cell lines. By targeting these long non-coding RNAs, many investigators have demonstrated the alleviation of ALI in various mouse models. Therefore, lncRNAs show great promise as a therapeutic target in ALI. This review provides the current state of knowledge about the relationship between lncRNAs in various biological processes in acute lung injury and its use as a potential therapeutic target.
- Published
- 2022